Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Rhumbline Advisers

Rhumbline Advisers grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) by 8.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 176,651 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,465 shares during the period. Rhumbline Advisers owned about 0.28% of Jazz Pharmaceuticals worth $27,559,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JAZZ. State of New Jersey Common Pension Fund D grew its stake in shares of Jazz Pharmaceuticals by 4.3% during the first quarter. State of New Jersey Common Pension Fund D now owns 35,262 shares of the specialty pharmaceutical company’s stock valued at $5,489,000 after acquiring an additional 1,445 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Jazz Pharmaceuticals by 2.8% during the first quarter. Arizona State Retirement System now owns 17,111 shares of the specialty pharmaceutical company’s stock valued at $2,664,000 after acquiring an additional 460 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 0.6% during the first quarter. Envestnet Asset Management Inc. now owns 40,976 shares of the specialty pharmaceutical company’s stock valued at $6,379,000 after acquiring an additional 239 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Jazz Pharmaceuticals by 4.6% in the first quarter. Commonwealth Equity Services LLC now owns 10,167 shares of the specialty pharmaceutical company’s stock worth $1,582,000 after purchasing an additional 447 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new position in Jazz Pharmaceuticals in the first quarter worth about $211,000. 92.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Samantha Pearce sold 1,063 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $155.00, for a total transaction of $164,765.00. Following the sale, the senior vice president now owns 11,309 shares of the company’s stock, valued at $1,752,895. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Bruce C. Cozadd sold 45,185 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $134.93, for a total transaction of $6,096,812.05. Following the sale, the chief executive officer now owns 374,028 shares of the company’s stock, valued at $50,467,598.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Samantha Pearce sold 1,063 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $155.00, for a total value of $164,765.00. Following the sale, the senior vice president now directly owns 11,309 shares in the company, valued at approximately $1,752,895. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,211 shares of company stock valued at $7,780,391. Insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JAZZ. Morgan Stanley lifted their price target on Jazz Pharmaceuticals from $174.00 to $187.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 4th. BMO Capital Markets lifted their price target on Jazz Pharmaceuticals from $185.00 to $188.00 and gave the stock an “outperform” rating in a research note on Thursday, August 4th. Needham & Company LLC decreased their price target on Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating for the company in a research note on Thursday, November 10th. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Finally, SVB Leerink raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a report on Thursday, August 4th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $202.50.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $151.26 on Thursday. The business’s 50 day moving average is $139.56 and its 200-day moving average is $148.16. The company has a quick ratio of 2.27, a current ratio of 3.16 and a debt-to-equity ratio of 2.07. Jazz Pharmaceuticals plc has a twelve month low of $117.64 and a twelve month high of $169.98.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Featured Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.